Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266240, C544S284000, C544S293000
Reexamination Certificate
active
07084147
ABSTRACT:
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
REFERENCES:
patent: 4074057 (1978-02-01), Kawamatsu et al.
patent: 4166735 (1979-09-01), Pilgram et al.
patent: 5457105 (1995-10-01), Barker
patent: 5480883 (1996-01-01), Spada et al.
patent: 5616582 (1997-04-01), Barker
patent: 5646153 (1997-07-01), Spada et al.
patent: 5654307 (1997-08-01), Bridges et al.
patent: 5710158 (1998-01-01), Meyers et al.
patent: 5773476 (1998-06-01), Chen et al.
patent: 5789427 (1998-08-01), Chen et al.
patent: 5821246 (1998-10-01), Brown et al.
patent: 43 08 014 (1994-09-01), None
patent: 0 370 704 (1990-05-01), None
patent: 0 414 386 (1991-02-01), None
patent: 0 452 002 (1991-10-01), None
patent: 0534 341 (1993-03-01), None
patent: 0 566 226 (1993-10-01), None
patent: 86/06718 (1986-11-01), None
patent: 93/13097 (1993-06-01), None
patent: 93/17682 (1993-09-01), None
patent: 93/18035 (1993-09-01), None
patent: 94/04526 (1994-03-01), None
patent: 95/00511 (1995-01-01), None
patent: 95/15758 (1995-06-01), None
patent: 95/19774 (1995-07-01), None
patent: 95/24190 (1995-09-01), None
patent: 96/09294 (1996-03-01), None
patent: 96/15118 (1996-05-01), None
patent: 96/16960 (1996-06-01), None
patent: 96/30347 (1996-10-01), None
patent: 96/40142 (1996-12-01), None
patent: 97/03069 (1997-01-01), None
patent: 97/13771 (1997-04-01), None
patent: 97/18212 (1997-05-01), None
patent: 97/30034 (1997-08-01), None
patent: 97/30035 (1997-08-01), None
patent: 97/38983 (1997-10-01), None
patent: 98/02434 (1998-01-01), None
patent: 98/02437 (1998-01-01), None
patent: 98/02438 (1998-01-01), None
patent: 98/13354 (1998-04-01), None
patent: 98/14451 (1998-04-01), None
patent: 99/0636 (1999-02-01), None
patent: 99/35132 (1999-07-01), None
patent: 99/35146 (1999-07-01), None
Zydowsky et al., “Synthesis and In Vitro Evaluation of Fused Ring Heterocycle-Containing Angiotensin II Antagonists”, 1994, Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 1, pp. 173-176.
Robba et al., “Thienopyrimidines—II Etude De La Thieno [3,2-d] Pyrimidine et de Quelques Derives”, 1971, Tetrahedron vol. 27, pp. 487-499.
Hunter, “A Thousand and One Protein Kinases”, Cell, vol. 50, pp. 823-829.
Modjtahedi et al., “EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN”, May 14, 1998, International Journal of Oncology, vol. 13, pp. 335-342.
Hung et al., “Basic Science of HER-2
eu: A Review”, Aug. 1999, Seminars in Oncology, vol. 26, No. 4, Suppl. 12, pp. 51-59.
J.R. Woodburn, “The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy”, 1999, Pharmacol Ther., vol. 82, Nos. 2-3, pp. 241-250.
Ullrich et al., “Signal Transduction by Receptors with Tyrosine Kinase Activity”, Apr. 20, 1990, Cell, vol. 61, pp. 203-212.
Bridges et al, “Tyrosine Kinase Inhibitors”, J Med. Chem., vol. 39, No. 1, Jan. 5, 1996, pp. 267-276.
Rewcastle et al., “Tyrosine Kinase Inhibitors”, J. Med. Chem., vol. 38, No. 18, 1995, pp. 3482-3487.
G.W. Rewcastle et al., “Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]pyrimidines are potent ATP binding sit inhibitors of the tyrosine kinase function of the epidermal growth factor receptor”, Journal of Medicinal Chemistry, 1996, vol. 39, No. 9, pp. 1823-1835.
Y. Katsura et al., “Studies on antiulcer drugs. V. Synthesis and antiulcer activity of aralkybenzozoles”, Chemical and Pharmaceutical Bulletin, 1992, vol. 40, No. 8, pp. 2062-2072.
T. Shoda et al., “Studies on antidiabetic agents. II. Synthesis of 5-[4-(methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione and its derivatives”, Chemical and Pharmaceutical Bulletin, 1982, vol. 30, pp. 3580-3600.
G.W. Rewcastle et al., “Synthesis of 6-substituted pyrido[3, d-d]pyrimidine-4(3H)-ones via directed lithiation of 2-substituted 5-aminopyridine derivatives”, Journal of the Chemical Society, Perkins Transactions1., 1996, pp. 2221-2226.
A.F. Wilks, Progress in Growth Factor Research, 1990, 2, pp. 97-111.
S.A. Courtneidge, Dev. Supp. I, 1993, pp. 57-64.
J.A. Cooper, Semin. Cell Biol., 1994, 5(6), pp. 377-387.
R.F. Paulson, Semin. Immunol., 1995, 7(4), pp. 267-277.
A.C. Chan, Curr. Opin. Immunol., 1996, 8(3), pp. 394-401.
Dvir et al., J. Cell. Biol., 1991, 113, pp. 857-865.
Buchdunger et al., Proc. Natl. Acad. Sci. USA; 1991, 92, pp. 2558-2562.
Klausner and Samelson, Cell; 1991, 64, pp. 875-878.
Berkois, Blood; 1992, 79(9), pp. 2446-2454.
Salari et al., FEBS; 1990, 263(1), pp. 104-108.
Ohmichi et al., Biochemistry, 1992, 31, pp. 4034-4039.
L.K. Shawyer, DDT, 1997, 2(2), pp. 50-63.
Pharmaceutical Research, 1986, 3(6), p. 318.
C.E. Housecroft et al., Inorg. Chem., 1991, 30(1), pp. 125-130.
H. Sato et al., Bioorganic and Medicinal Chemistry Letters, 1995, 5(3), pp. 233-236.
J. Org. Chem., 1990, 55, pp. 1379-1390.
Helv. Chim. Acta., 1983, 66(4), p. 1046.
T.R. Kelly and F. Lang, Tetrahedron Lett., 36, 9293, 1995.
J. Chem. Soc., Chem. Commun., 1988, p. 560.
V.P. Semenov and A.N. Studenikov, “Synthesis of 7-iodo-4aminoquinoline derivatives”, Khim Geterotsikl. Soedin., 1980, Issue 7, pp. 972-975.
R. Dempsy and E. Skito, Biochemistry, 30, 1991, p. 8480.
J. Org. Chem., 1992, 57(11), pp. 3126-3131.
A. Lee and W-C Dai, Tetrahedron, 1997, 53(3), pp. 859-868.
Cockerill George Stuart
Lackey Karen Elizabeth
Kifle Bruck
Lemanowicz John L.
SmithKline Beecham Corporation
LandOfFree
Anilinoquinazaolines as protein tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anilinoquinazaolines as protein tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anilinoquinazaolines as protein tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3647883